FeesSafety
Pluang+

Eli Lilly leads obesity drug market with strong sales and promising pipeline, securing its top position.

Market News
23 Nov 2026, 01:03 WIB
Prosper Junior Bakiny
View Source
Bullish
Eli Lilly leads obesity drug market with strong sales and promising pipeline, securing its top position.

Eli Lilly dominates the obesity drug market with its approved treatments Zepbound and Foundayo, showing strong sales growth—Zepbound's revenue rose 49% to $5.4 billion in Q3 2026. The company’s pipeline includes promising candidates like retatrutide and EloraTZP, which have shown greater weight loss in trials and may expand the market further. Despite competition, Eli Lilly's innovative drugs and strong pricing power position it to maintain growth and market leadership over the next five years, supporting a premium stock valuation.

Eli Lilly's stock trades at USD 1,347.11 on Pluang as of Nov 23, 2026 02:11 WIB, showing a slight 0.30% decline in one day. The company holds a market cap of $1.20 trillion and an enterprise value of $1.24 trillion, reflecting its dominant position in the health sector. This robust valuation aligns with the article's focus on Eli Lilly's expanding obesity drug pipeline and strong market leadership.

More News (LLY)

Eli Lilly leads obesity drug market with strong sales and promising pipeline despite rising competition.

Eli Lilly leads obesity drug market with strong sales and promising pipeline despite rising competition.

Eli Lilly remains a leader in the obesity drug market with its approved products Zepbound and Foundayo showing strong sales growth. New pipeline candidates like retatrutide and EloraTZP have demonstrated greater weight loss in trials, positioning the...

Market News
Bullish
6 hours ago
Eli Lilly's weight loss drugs drive 39% revenue surge, fueling strong growth outlook.

Eli Lilly's weight loss drugs drive 39% revenue surge, fueling strong growth outlook.

Eli Lilly has seen its revenue soar thanks to its dominance in the weight loss drug market, with products like Mounjaro and Zepbound contributing to a 39% revenue increase to over $24 billion recently. The company leads in GLP-1 drugs, which regulate...

Market News
Bullish
15 hours ago
Eli Lilly's Zepbound shows strong weight loss results in adolescents, opening a $6.5B market opportunity.

Eli Lilly's Zepbound shows strong weight loss results in adolescents, opening a $6.5B market opportunity.

Eli Lilly's weight loss drug Zepbound demonstrated significant effectiveness in a clinical trial involving adolescents aged 12 to 17, with participants losing an average of 40 pounds and showing improved health markers. This success could lead to lab...

Company Fundamentals
Bullish
1 day ago
Novo Nordisk rebounds with successful GLP-1 pill launch, boosting dividend yield amid competitive weight-loss market.

Novo Nordisk rebounds with successful GLP-1 pill launch, boosting dividend yield amid competitive weight-loss market.

Novo Nordisk lost its lead in the GLP-1 weight-loss shot market to Eli Lilly due to supply issues but has rebounded strongly with its new GLP-1 pill, which captured 80% of new oral treatment patients in Q3 2026. The company is shifting to a volume-dr...

Market News
Bullish
1 day ago
Eli Lilly's Zepbound shows strong weight loss results in adolescents, opening a $6.5B market opportunity.

Eli Lilly's Zepbound shows strong weight loss results in adolescents, opening a $6.5B market opportunity.

Eli Lilly's weight loss drug Zepbound demonstrated significant effectiveness in a clinical trial involving adolescents aged 12 to 17, with participants losing an average of 40 pounds and notable improvements in health markers. This success could lead...

Company Fundamentals
Bullish
1 day ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App